EU lays out pros and cons to on­shoring more API pro­duc­tion

As the US em­barks on a bil­lion-dol­lar ini­tia­tive to on­shore ac­tive phar­ma­ceu­ti­cal in­gre­di­ent (API) man­u­fac­tur­ing, the Eu­ro­pean Union re­leased a re­port ear­li­er this month weigh­ing the pros and cons of any pos­si­ble reshoring of API pro­duc­tion.

The 58-page re­port notes that over the past decade, med­i­cine short­ages have been in­creas­ing through­out Eu­rope, as they have across the pond, with con­cerns raised that out­sourc­ing API man­u­fac­tur­ing abroad may have con­tributed to dis­rup­tions in the sup­ply chain. A pro­pos­al to reshore API man­u­fac­tur­ing to EU mem­ber states has been pro­posed, but it’s un­clear if it will gain trac­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.